



F16.2


Docket No. M1015/7071 Diagnostic Tumor Markers, Drug Screening for Tumorigenesis Inhibition...






Docket No. M1015/7071 Diagnostic Tumor Markers, Drug Screening for Tumorigenesis Inhibition...

Average % Cell Growth From 0-48 Hours




Screening for Tumorigenesis Diagnostic Tumor Markers, Drug


Docket No. M1015/7071



Fi6.6




F16.7




F16.9


Docket No. M1015/7071 Diagnostic Tumor Markers, Drug Screening for Tumorigenesis Inhibition...



01.017




F16.11



F16.12


Docket No. M1015/7071 Diagnostic Tumor Markers, Drug Screening for Tumorigenesis Inhibition...



Diagnostic Tumor Markers, Drug Screening for Tumorigenesis

Docket No. M1015/7071

F16 15




101

Binding Assay

Docket No. M1015/7071

Diagnostic Tumor Markers, Drug
Screening for Tumorigenesis
Inhibition...




-10mm Ft Pephole -Series1 37 Et=7 Etomoxir + Peptide łime ·78H=7 F16.18 80 70 09 50 40 30 20 10 % Growth ...noitididal Screening for Tumorigenesis

Diagnostic Tumor Markers, Drug

Docket No. M1015/7071

Docket No. M1015/7071 Diagnostic Tumor Markers, Drug Screening for Tumorigenesis Inhibition...



PSMGFR Colored + Lysofe (+finst)

PSMGFR

F16.20